Researchers find new method to combat common childhood illness

April 18, 2014 by April Reese Sorrow
Biao He, a Georgia Research Alliance Distinguished Investigator and member of the Faculty of Infectious Diseases, developed a flu vaccine that is 100 percent effective in protecting against H1N1 and more than 60 percent effective in protection against the most virulent strain H5N1 when tested in the mouse model.

Almost all children are infected with respiratory syncytial virus by the time they are two. Most recover quickly from cold-like symptoms. But for others, RSV can cause serious lung infections, such as bronchiolitis and pneumonia, which lands an estimated 75,000 to 125,000 children in the hospital each year, according to the U.S. Centers for Disease Control and Prevention.

New research from the University of Georgia could lead to the first RSV -and keep many of those children out of the hospital.

"RSV is the most important cause of pediatric viral and is a major cause of morbidity and mortality among infants as well as immunocompromised subjects and the elderly," said Biao He, a professor of infectious diseases in the UGA College of Veterinary Medicine and the study's lead author. "Many other researchers tried to develop a RSV vaccine but were unsuccessful. Our approach is different from all previous attempts, and now we have shown it works in animals."

Several approaches to vaccination have been evaluated over the years, but there are currently no licensed RSV vaccines and no effective treatments for severe RSV. A vaccine developed using formalin-inactivated RSV and tested in 1966 left children unprotected; many infants still caught RSV, suffered worse symptoms and had to be hospitalized. Two toddlers died from enhanced disease symptoms.

In He's lab, the journey to a successful RSV vaccine-it has been tested and works in a mouse model-started with a virus that causes respiratory infection in dogs. Canine parainfluenza virus, also known as parainfluenza virus 5 (PIV5), can be modified to deliver antigens against pathogens like RSV.

Using genetic engineering, He and his team of researchers inserted genes coding antigens of RSV into PIV5, creating a recombinant vaccine. Placing just a few genes from RSV into the genome of PIV5, the carrier virus exposes a person's cells to antigens of pathogenic virus, allowing them to generate immunity that will protect against future infections.

He's research shows that a single dose of vaccine protected a mouse against RSV infection, according to results published in the April issue of Vaccine. In this case, the vaccine was administered through the mouse's nose. Using the modified PIV5 as a delivery mechanism to generate immune responses in humans and other animals to important pathogens allows He's team to create vaccines that will protect against a variety of current and future infectious agents.

Severe RSV infection can contribute to wheezing and asthma later in life. Unlike infection by other respiratory viruses, RSV does not induce long-lasting protective immunity against subsequent infection, so most individuals are infected multiple times throughout the course of their lives.

"Our hope is that this vaccine will protect people for life," He said. "Even if we create a RSV vaccine that protects children and at-risk adults for only five years, that will be worth it."

"PIV5-based vaccine is safe, stable, efficacious, cost-effective to produce and overcomes pre-existing anti-vector immunity," said He, who also is the Fred C. Davison Distinguished University Chair in Veterinary Medicine and a member of the UGA Faculty of Infectious Diseases. "In this work, we have shown that PIV5-based RSV vaccine candidates have the potential to be an effective vaccine, providing an additional option for RSV vaccine development."

Explore further: Study offers clues to making vaccine for infant respiratory illness

More information: Shannon I. Phan, Zhenhai Chen, Pei Xu, Zhuo Li, Xiudan Gao, Stephanie L. Foster, Michael N. Teng, Ralph A. Tripp, Kaori Sakamoto, Biao He, "A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)," Vaccine, Available online 8 April 2014, ISSN 0264-410X, dx.doi.org/10.1016/j.vaccine.2014.03.049.

Related Stories

Study offers clues to making vaccine for infant respiratory illness

April 25, 2013
An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common—and sometimes very serious—childhood disease. The findings, ...

One step closer to vaccine for common respiratory disease

June 17, 2013
Young children and the elderly are especially susceptible to respiratory syncytial virus. The three-dimensional structure of respiratory syncytial virus has been solved by an international team from Finland and Switzerland.

Molecular dissection of respiratory syncytial virus infection

November 12, 2013
A study published this week in PLOS Medicine reveals profound systemic dysregulation of the immune response induced by RSV infection in young children and suggest that molecular markers might be able to predict disease severity.

Researchers find genetic trigger for RSV-induced infant hospitalizations

April 8, 2014
Researchers at UNC School of Medicine have pinpointed a viral protein that plays a major role in making respiratory syncytial virus (RSV) the most common cause of hospitalization in children under one year of age.

Study suggests a ‘sibling vaccine’ could prevent deaths of babies worldwide

February 7, 2014
(Medical Xpress)—New research from the University of Warwick into a common virus which can be fatal for babies under six months suggests a strategy of vaccinating older siblings could reduce deaths and serious illness in ...

Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide

November 18, 2013
(Medical Xpress)—Scientists have identified the genetic signature of respiratory syncytial virus (RSV), the leading cause of infant hospitalizations around the world. The work is a key step toward a better understanding ...

Recommended for you

How a poorly explored immune cell may impact cancer immunity and immunotherapy

November 17, 2017
The immune cells that are trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most research has targeted these co-called effector T-cells.

Asthma attacks reduced in tree-lined urban neighborhoods

November 17, 2017
People living in polluted urban areas are far less likely to be admitted to hospital with asthma when there are lots of trees in their neighbourhood, a study by the University of Exeter's medical school has found.

How the immune system identifies invading bacteria

November 16, 2017
The body's homeland security unit is more thorough than any airport checkpoint. For the first time, scientists have witnessed a mouse immune system protein frisking a snippet of an invading bacterium. The inspection is far ...

Can asthma be controlled with a vitamin supplement?

November 16, 2017
The shortness of breath experienced by the nearly 26 million Americans who suffer from asthma is usually the result of inflammation of the airways. People with asthma typically use albuterol for acute attacks and inhaled ...

Newly found immune defence could pave way to treat allergies

November 16, 2017
Scientists have made a fundamental discovery about how our body's immune system clears harmful infections.

Study finds asthma and food allergies predictable at age 1

November 15, 2017
Children at one year old who have eczema or atopic dermatitis (AD) and are sensitized to an allergen are seven times more likely than other infants to develop asthma, and significantly more likely to have a food allergy by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.